Merck Commences Tender Offer to Acquire Terns Pharmaceuticals for $53.00 Per Share in Cash

summarizeSummary

Merck's subsidiary has formally commenced a tender offer to acquire all outstanding shares of Terns Pharmaceuticals for $53.00 per share in cash, following the definitive merger agreement announced on March 25, 2026.

check_boxKey Events

• Tender Offer Commencement

  Merck's subsidiary, Thailand Merger Sub, Inc., has formally commenced a tender offer to acquire all outstanding shares of Terns Pharmaceuticals.

• Acquisition Price

  Shareholders are offered $53.00 per share in cash, representing a premium to recent trading prices and near the 52-week high.

• Board Recommendation

  Terns' Board of Directors unanimously recommends shareholders accept the offer and tender their shares.

• Transaction Value

  The acquisition is valued at approximately $6.73 billion, leading to Terns becoming a private entity.

auto_awesomeAnalysis

This SC TO-T filing marks the formal launch of the tender offer by Merck's subsidiary, Thailand Merger Sub, Inc., to acquire all outstanding shares of Terns Pharmaceuticals. The offer price of $53.00 per share in cash represents a premium to Terns' recent trading prices and is near its 52-week high, providing a clear exit for shareholders. The unanimous recommendation from Terns' Board of Directors signals strong internal support for the acquisition. This transaction, valued at approximately $6.73 billion, is a definitive, thesis-altering event that will result in Terns becoming a wholly-owned subsidiary of Merck and its shares being delisted. Shareholders should consider tendering their shares by the May 4, 2026 expiration date to realize the cash value.